# CHAMP: Study of NVK-002 in Children With Myopia

> **NCT03350620** · PHASE3 · COMPLETED · sponsor: **Vyluma, Inc.** · enrollment: 670 (actual)

## Conditions studied

- Myopia

## Interventions

- **DRUG:** NVK-002 Concentration 1
- **DRUG:** NVK-002 Concentration 2
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03350620
- **Lead sponsor:** Vyluma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-20
- **Primary completion:** 2022-09-07
- **Final completion:** 2023-10-19
- **Target enrollment:** 670 (ACTUAL)
- **Last updated:** 2024-11-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03350620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03350620, "CHAMP: Study of NVK-002 in Children With Myopia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03350620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*